Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-transplantation Lymphoproliferative Disorders”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT02360111
What this trial is testing

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Who this might be right for
LeukemiaMyelodysplastic SyndromeNon-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)Ended earlyNCT01116232
What this trial is testing

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Barbara Ann Karmanos Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT00504634
What this trial is testing

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

Who this might be right for
Multiple Myeloma
M.D. Anderson Cancer Center 8
Very early researchLooking for participantsNCT06735690
What this trial is testing

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
City of Hope Medical Center 15
Not applicableStudy completedNCT07150468
What this trial is testing

Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells

Who this might be right for
Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Lymphoma, Multiple Myeloma
Asan Medical Center 146
Not applicableUnknownNCT01891578
What this trial is testing

Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation

Who this might be right for
Lymphoma
Armando Santoro, MD 23
Testing effectiveness (Phase 2)Study completedNCT00285389
What this trial is testing

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Who this might be right for
Mantle Cell Lymphoma
French Innovative Leukemia Organisation 39
Testing effectiveness (Phase 2)Study completedNCT02042391
What this trial is testing

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Who this might be right for
Posttransplant Lymphoproliferative Disorder
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03192397
What this trial is testing

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Who this might be right for
Acute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionChronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission+10 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT01283776
What this trial is testing

Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

Who this might be right for
Multiple MyelomaNon-Hodgkin-LymphomaHodgkin's Disease
University of Cologne 11
Early research (Phase 1)Study completedNCT00734890
What this trial is testing

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Lung CancerLymphomaLymphoproliferative Disorder+2 more
National Institutes of Health Clinical Center (CC) 18
Not applicableStudy completedNCT04189835
What this trial is testing

EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients

Who this might be right for
EBV InfectionEBV ViremiaEpstein-Barr Virus Associated Lymphoproliferative Disorder+1 more
University of Aarhus 509
Large-scale testing (Phase 3)Ended earlyNCT00573391
What this trial is testing

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Who this might be right for
Multiple Myeloma
University of Arkansas 5
Testing effectiveness (Phase 2)WithdrawnNCT01812720
What this trial is testing

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Mayo Clinic
Testing effectiveness (Phase 2)Study completedNCT00702403
What this trial is testing

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic Phase Chronic Myelogenous Leukemia+11 more
Fred Hutchinson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT01352286
What this trial is testing

Redirected Auto T Cells for Advanced Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 25
Testing effectiveness (Phase 2)Ended earlyNCT01044745
What this trial is testing

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+108 more
University of Nebraska 20
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Testing effectiveness (Phase 2)Study completedNCT00310037
What this trial is testing

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology 151
Testing effectiveness (Phase 2)Study completedNCT00005802
What this trial is testing

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Who this might be right for
Leukemia
Fred Hutchinson Cancer Center
Next Page
35